BeiGene, Ltd. (BGNE)
NASDAQ: BGNE · Real-Time Price · USD
207.25
+3.04 (1.49%)
Nov 4, 2024, 4:00 PM EST - Market closed
BeiGene Revenue
BeiGene had revenue of $929.17M in the quarter ending June 30, 2024, with 56.09% growth. This brings the company's revenue in the last twelve months to $3.10B, up 71.01% year-over-year. In the year 2023, BeiGene had annual revenue of $2.46B with 73.65% growth.
Revenue (ttm)
$3.10B
Revenue Growth
+71.01%
P/S Ratio
6.89
Revenue / Employee
$292,126
Employees
10,600
Market Cap
22.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Koninklijke Philips | 20.12B |
| Teva Pharmaceutical | 16.29B |
| Zimmer Biomet Holdings | 7.60B |
| STERIS | 5.23B |
| Moderna | 5.05B |
| Illumina | 4.43B |
| Hologic | 3.99B |
| The Cooper Companies | 3.80B |
BGNE News
- 7 days ago - BeiGene Mourns Death of Beloved Board Member Donald Glazer - Business Wire
- 14 days ago - BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma - Business Wire
- 19 days ago - BeiGene Highlights Waldenström's Macroglobulinemia Innovation at IWWM 2024 - Business Wire
- 4 weeks ago - Chinese Biopharmaceutical Stocks Surge with Positive Policy Impact - GuruFocus
- 5 weeks ago - BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers - Business Wire
- 5 weeks ago - Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors - Business Wire
- 6 weeks ago - BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy - Business Wire
- 2 months ago - Phonak + Advanced Bionics sponsor new family film, Rally Caps - Worldwide release on September 10th - Business Wire